NASDAQ:TBPH Theravance Biopharma Q4 2025 Earnings Results & Report $17.03 0.00 (0.00%) As of 10/7/2026 Theravance Biopharma reported Q4 2025 earnings on March 31, 2026. The company reported EPS of -$0.10, while revenue was $17.70 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeAfter Market Closes Theravance Biopharma EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersTheravance Biopharma Revenue ResultsActual Revenue$17.70 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTheravance Biopharma's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Theravance Biopharma Q4 2025 Earnings FAQ Did Theravance Biopharma beat earnings estimates for Q4 2025? Theravance Biopharma (NASDAQ:TBPH) reported earnings of -$0.10 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026. What was Theravance Biopharma's revenue for Q4 2025? Theravance Biopharma reported revenue of $17.70 million for Q4 2025. When is Theravance Biopharma's next earnings date? Theravance Biopharma's next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Theravance Biopharma on the company's earnings history page. Theravance Biopharma Earnings HeadlinesHead to Head Contrast: Lifecore Biomedical (NASDAQ:LFCR) & Theravance Biopharma (NASDAQ:TBPH)October 1, 2026 | americanbankingnews.comTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness IndexSeptember 24, 2026 | marketscreener.comM"The largest market in human history"SpaceX quietly filed paperwork describing what it calls the largest actionable total addressable market in human history, valued at 28.5 trillion dollars. Former Wall Street CEO Dylan says the opportunity has nothing to do with the SpaceX IPO, self-driving cars, or robotics. Instead, it centers on an obscure AI firm Elon has reportedly been paying since 2012.October 8 at 1:00 AM | Behind the Markets (Ad)Zymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.September 24, 2026 | de.marketscreener.comDTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI IndexSeptember 23, 2026 | marketscreener.comMTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Global BMI IndexSeptember 22, 2026 | marketscreener.comMSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and other serious conditions. The company’s work centers on therapies designed to address unmet needs in areas such as chronic obstructive pulmonary disease (COPD) and related respiratory disorders. Its principal commercial product is YUPELRI (revefenacin), an inhaled long-acting muscarinic antagonist used as a once-daily maintenance treatment for COPD. YUPELRI is commercialized in collaboration with Viatris. Theravance also receives royalties associated with certain respiratory products developed through its collaboration with GlaxoSmithKline, including the products marketed as Trelegy Ellipta. Theravance Biopharma was established in 2013 following the separation of its biopharmaceutical operations from Theravance, Inc. The company is headquartered in Dublin, Ireland, and relies on commercial and development partners to support the availability of its medicines in the United States and selected international markets. Rick E. Winningham has served as the company’s chief executive officer since its formation.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
